Ad spend helps Crestor outpace Lipitor growth: Bloomberg.com

Share this article:
AstraZeneca outspent rivals Pfizer and Merck by 30% on consumer advertising for Crestor, helping the drug become the fastest-growing cholesterol treatment, Bloomberg.com reported. AstraZeneca spent $166.5 million on Crestor TV, print and radio promotion to consumers in 2006 to November, the Web site reported, citing data from Nielsen Monitor-Plus. That number compares with $128 million spent by Merck on Vytorin and $104 million spent by Schering-Plough on Zetia. Crestor is taking Pfizer’s Lipitor, the top-selling cholesterol-lowering treatment and the world’s best-selling prescription medicine, with 2006 global sales of $12.8 billion. Pfizer spent approximately $18 million on consumer advertising for Lipitor in 2006 to November, with sales gaining 15% in the third quarter. During the third quarter of 2006, Crestor sales rose 64% to outpace Vytorin, according to Bloomberg.com.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions